KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Debt Issuances for 4 consecutive years, with -$680000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$680000.0, compared with a TTM value of -$1.5 million through Dec 2025, down 100.14%, and an annual FY2025 reading of $645.7 million, changed N/A over the prior year.
  • Long-Term Debt Issuances was -$680000.0 for Q4 2025 at Alnylam Pharmaceuticals, up from -$777000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.0 billion in Q3 2022 and bottomed at -$250.0 million in Q3 2021.
  • Average Long-Term Debt Issuances over 3 years is $191.4 million, with a median of -$728500.0 recorded in 2022.
  • Peak annual rise in Long-Term Debt Issuances hit 506.76% in 2022, while the deepest fall reached 506.76% in 2022.
  • Year by year, Long-Term Debt Issuances stood at -$250.0 million in 2021, then skyrocketed by 99.69% to -$777000.0 in 2022, then increased by 12.48% to -$680000.0 in 2025.
  • Business Quant data shows Long-Term Debt Issuances for ALNY at -$680000.0 in Q4 2025, -$777000.0 in Q4 2022, and $1.0 billion in Q3 2022.